We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Intestinal Microbiome in Obese Kids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00816296
Recruitment Status : Withdrawn (PI has left institution)
First Posted : January 1, 2009
Last Update Posted : August 24, 2015
Sponsor:
Information provided by:
Medical College of Wisconsin

Brief Summary:
The goal of this study is to investigate comparisons between the intestinal microbiome in patients with obesity and in patients with obesity and Non-Alcoholic Fatty Liver Disease (NAFLD). With this protocol we hope to better understand how the microbiome of each individual works with disease progression.

Condition or disease Intervention/treatment
Obesity Non-Alcoholic Fatty Liver Disease Other: Blood Draw Other: Stool collection Other: BodPod Measurement Other: Liver Ultrasound

Detailed Description:

The goal of this study is to investigate and compare the composition of the intestinal microbiome in patients with obesity only to patients with obesity and Non-Alcoholic Fatty Liver Disease (NAFLD). In addition, we will investigate the relationship between alterations in the intestinal microbiome, immune activation, and the progression of NAFLD to Non-Alcoholic Steatohepatitis (NASH). We hypothesize that alterations in the intestinal microbiome are associated with increased immune activation and progression of obesity associated NAFLD. Based on this hypothesis we propose the following aims:

Aim 1. Identify and enroll pediatric cohort with obesity or obesity/NAFLD to study the role of the intestinal microbiome on the development of NAFLD.

  1. Enroll participants through the NEW Kids program for treatment of pediatric obesity at Children's Hospital of Wisconsin (CHW). Identify and classify participants through initial clinical evaluation, collect clinical metadata, and obtain and process blood and stool samples for analysis. Demonstrate feasibility by showing that participants can be recruited and participate in the specific study protocol.
  2. Follow study population through nutritional/exercise intervention, with follow up collection of clinical data, stool, and blood samples.

Aim 2. Characterize the intestinal microbiome through quantitative PCR and high throughput sequencing analysis of stool specimens in participants with obesity and obesity/NAFLD.

  1. Demonstrate feasibility by showing that sampling aliquots from patient fecal samples can be successfully analyzed by proposed methods and yield consistent results for duplicate samples.
  2. Compare sequencing results and metagenomic analysis for study groups with particular attention to bacterial composition and metabolic capacity associated with energy harvest, lipid and carbohydrate transport, enhancement of epithelial barrier integrity, and choline metabolism.
  3. Investigate whether intervention (nutritional/exercise) results in longitudinal alterations in the intestinal microbiome.

Aim 3. Characterize evidence of systemic inflammation by C-reactive protein (CRP), Tumor necrosis factor alpha (TNF-alpha)Transforming growth factor beta 1 (TGF-beta and LPS Binding Protein (LBP) levels, and analyze results in relationship to the intestinal microbiome and the presence of NAFLD.

  1. Compare levels of systemic inflammatory markers of participants with obesity vs. obesity/NAFLD
  2. Investigate whether intervention (nutritional/exercise) results in longitudinal alterations in systemic inflammation.

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Evaluation of the Intestinal Microbiome in Obese Children With and Without Non-Alcoholic Fatty Liver Disease
Study Start Date : October 2008
Estimated Primary Completion Date : October 2011
Estimated Study Completion Date : October 2012


Group/Cohort Intervention/treatment
Controls
Obese (BMI>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
Other: Blood Draw
2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.

Other: Stool collection
Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.

Other: BodPod Measurement
Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.

Other: Liver Ultrasound
A liver ultrasound will be performed at study entry and 6 months after study entry.

Liver Disease
Obese (BMI>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
Other: Blood Draw
2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.

Other: Stool collection
Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.

Other: BodPod Measurement
Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.

Other: Liver Ultrasound
A liver ultrasound will be performed at study entry and 6 months after study entry.




Primary Outcome Measures :
  1. Alterations in the intestinal microbiome are associated with increased immune activation and progression of obesity associated NAFLD. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Characterize the intestinal microbiome through quantitative analysis of stool samples in participants with obesity and those with obesity and NAFLD. [ Time Frame: 3 years ]
  2. Characterize inflammatory markers of participants with obesity versus those obese participants that also have NAFLD. [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
Participants will need to give a blood and stool samples on 3 separate occasions.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Gastroenterology Clinic at Children's Hospital of Wisconsin
Criteria

Inclusion Criteria:

  • Age 5-18 Years old
  • Willing to consent/undergo necessary procedures
  • Obese (BMI>30)
  • Speak English or Spanish

Exclusion Criteria:

  • any other causes of liver disease
  • any chronic illnesses or life threatening conditions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00816296


Locations
Layout table for location information
United States, Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: Vincent Biank, MD Children's Hospital and Health System Foundation, Wisconsin
Publications:

Layout table for additonal information
Responsible Party: Vincent Biank, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT00816296    
Other Study ID Numbers: CHW 08/159
GC 727
First Posted: January 1, 2009    Key Record Dates
Last Update Posted: August 24, 2015
Last Verified: August 2015
Keywords provided by Medical College of Wisconsin:
NAFLD
Obesity
Microbiome
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases